Ireland
SynOx Therapeutics, an innovative player in the Biotechnology and Health and Wellness sectors, is strategically positioned to address critical needs in cancer treatment. Founded in November 2020, this Ireland-based company is committed to developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and potentially other indications. Their mission underscores the unmet clinical needs of patients suffering from TGCT.
Backed by a robust syndicate of investors renowned for their experience in building biopharma companies, SynOx Therapeutics reinforces its credibility in the medical community. Recently, the company secured a significant $35 million Debt Financing investment from Hercules Capital on April 30, 2024. Such financial support not only validates SynOx's potential in tackling TGCT but also ensures the necessary capital for advancing their clinical endeavors. This positions the company favorably for growth and successful trials ahead.
